Adaptimmune (ADAP) Files Form 144 for 13,829,778 ADRs on NASDAQ

Rhea-AI Filing Summary

Form 144 notice for Adaptimmune Therapeutics plc (ADAP): A proposed sale of 13,829,778 American Depositary Receipts is being submitted for sale through J.P. Morgan Securities LLC on or about 08/15/2025 on NASDAQ. The form lists the issuer's total shares outstanding as 1,590,309,546 and reports an aggregate market value for the proposed sale of 981,914. The ADRs were acquired in private placements from the issuer on several dates between 09/23/2014 and 09/05/2018, with recorded quantities for each acquisition and cash as the nature of payment. No securities were reported sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information.

Positive

• Brokered sale through reputable broker (J.P. Morgan Securities LLC) which suggests orderly execution
• Detailed acquisition history provided, including dates and quantities from 2014 to 2018

Negative

• Proposed sale of 13,829,778 ADRs increases potential supply of shares on NASDAQ
• Aggregate market value reported (981,914) lacks explicit currency/unit context within this text

Insights

Securities Compliance Analyst

TL;DR: Routine Form 144 filing disclosing a proposed sale of ADRs through a broker with acquisition history provided; no recent sales reported.

The filing documents a proposed brokered sale of 13,829,778 ADRs on NASDAQ via J.P. Morgan, including detailed acquisition dates and quantities from multiple private placements between 2014 and 2018. The form properly includes the filers representation about material undisclosed information and indicates no securities sold in the past three months. From a compliance perspective, the submission contains the core elements required for Rule 144 notices: class of securities, broker, intended sale date, outstanding shares, acquisition history, and signature/representation language. The aggregate market value field is reported as 981,914, which should be verified for currency/units in the underlying filing record.

Equity Capital Markets Specialist

TL;DR: Disclosure indicates a sizable ADR block offered through a major broker, with multi-year holding history—typical institutional/insider liquidity action.

The schedule shows the ADRs were acquired in multiple private placements from the issuer with cash payment, suggesting the holder obtained the securities from early financings. The planned use of J.P. Morgan Securities LLC to execute a sale on or about 08/15/2025 is consistent with standard market execution for a large block. The filing does not provide price guidance, tranche timing, or whether the sale will be structured to comply with volume limitations under Rule 144 beyond the notice itself. For investors, the document is a disclosure of potential supply; it does not by itself quantify immediate market impact.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Receipts	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	13829778	981914	1590309546	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Receipts	09/23/2014	Private Placement	Issuer			9878166	09/23/2014	Cash
American Depositary Receipts	03/22/2017	Private Placement	Issuer			2145000	03/22/2017	Cash
American Depositary Receipts	03/21/2018	Private Placement	Issuer			17474	03/21/2018	Cash
American Depositary Receipts	03/22/2018	Private Placement	Issuer			144929	03/22/2018	Cash
American Depositary Receipts	03/23/2018	Private Placement	Issuer			49015	03/23/2018	Cash
American Depositary Receipts	03/26/2018	Private Placement	Issuer			95194	03/26/2018	Cash
American Depositary Receipts	03/27/2018	Private Placement	Issuer			1000000	03/27/2018	Cash
American Depositary Receipts	09/05/2018	Private Placement	Issuer			500000	09/05/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for ADAP disclose?

The form discloses a proposed sale of 13,829,778 American Depositary Receipts through J.P. Morgan Securities LLC on or about 08/15/2025 on NASDAQ.

How many ADAP shares are outstanding according to this filing?

The filing reports 1,590,309,546 shares or ADRs outstanding.

When and how were the ADRs being offered acquired?

The ADRs were acquired in multiple private placements from the issuer between 09/23/2014 and 09/05/2018, with cash recorded as the nature of payment.

Did the filer sell any securities in the past three months?

The filing states: Nothing to Report for securities sold during the past three months.

Does the filing indicate any undisclosed material information about ADAP?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.